Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P11511
UPID:
CP19A_HUMAN
Alternative names:
CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Estrogen synthase
Alternative UPACC:
P11511; Q16731; Q3B764; Q58FA0; Q8IYJ7
Background:
Aromatase, also known as Cytochrome P450 19A1, plays a pivotal role in steroid metabolism, converting androgens to estrogens. This enzyme's activity is crucial for the balance of sex hormones in the body.
Therapeutic significance:
Aromatase is linked to Aromatase excess syndrome and Aromatase deficiency, conditions altering estrogen levels and affecting sexual development. Targeting Aromatase offers a pathway to treat these disorders, highlighting its therapeutic potential.